Title: FDA Warns of Rare Risk of Secondary Cancer Associated with CAR-T Therapies Introduction The U.S. Food and Drug Administration...
The Creation of a Living Biobank of Brain Metastasis Samples for Advancing Personalized Medicine Brain metastasis, the spread of cancer...
The Food and Drug Administration (FDA) has recently mandated additional cancer warnings for Chimeric Antigen Receptor T-cell (CAR-T) therapies. This...
Strand Therapeutics, a leading biotechnology company specializing in developing innovative RNA-based therapies, has recently received approval from the Food and...
Gilead’s ADC Medicine Falls Short of Target in Highly Monitored Lung Cancer Study Gilead Sciences, a leading biopharmaceutical company, recently...
Promising Results of CAR T-Cell Therapy in Early Phase Trial for Pancreatic and Gastric Cancers Pancreatic and gastric cancers are...
Phase 3 Trials of Revolutionary Cancer Vaccine Near Completion with Minimal Side Effects Cancer has long been one of the...
Understanding the Crucial Stages of DNA Repair: Insights from Scientists DNA repair is a fundamental process that ensures the integrity...
The Role of Genome Instability in Trisomy 21-Associated Myeloid Malignancies: A Study on Leukemia Introduction: Trisomy 21, also known as...
The Food and Drug Administration (FDA) has recently approved a groundbreaking drug called Balversa (erdafitinib) for the treatment of FGFR3+...
Successful Treatment of Multiple Myeloma in a Patient Following Hepatitis Treatment Multiple myeloma is a type of cancer that affects...
Novocure, a global oncology company specializing in the development of innovative cancer therapies, has recently submitted a Premarket Approval (PMA)...
NICE Issues Recommendation for Groundbreaking Breast Cancer Medication Breast cancer is one of the most common types of cancer affecting...
Understanding the Potential of Epigenetic Editing: Harnessing the Power of CRISPR without DNA Alteration In recent years, the revolutionary gene-editing...
Title: Promising Results: First Patient in Phase 1 Clinical Trial of PMB-CT01 Achieves Complete Remission for Relapsed and Refractory B-cell...
